Novavax, Inc. (NVAX)

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of $1.46 billion. The enterprise value is $674.00 million.

Market Cap	1.46B
Enterprise Value	674.00M

Important Dates

The next estimated earnings date is Monday, November 11, 2024, before market open.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Novavax has 160.09 million shares outstanding. The number of shares has increased by 54.60% in one year.

Current Share Class	160.09M
Shares Outstanding	160.09M
Shares Change (YoY)	+54.60%
Shares Change (QoQ)	+18.54%
Owned by Insiders (%)	0.30%
Owned by Institutions (%)	47.43%
Float	143.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.19
Forward PS	2.86
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.04

Current Ratio	1.04
Quick Ratio	0.93
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-18.79

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-10.21%
Return on Capital (ROIC)	n/a
Revenue Per Employee	$640,095
Profits Per Employee	-$190,754
Employee Count	1,543
Asset Turnover	0.56
Inventory Turnover	50.70

Taxes

In the past 12 months, Novavax has paid $5.46 million in taxes.

Income Tax	5.46M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.18% in the last 52 weeks. The beta is 2.09, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.09
52-Week Price Change	+29.18%
50-Day Moving Average	11.85
200-Day Moving Average	9.83
Relative Strength Index (RSI)	31.02
Average Volume (20 Days)	6,203,220

Short Selling Information

The latest short interest is 35.72 million, so 22.31% of the outstanding shares have been sold short.

Short Interest	35.72M
Short Previous Month	33.88M
Short % of Shares Out	22.31%
Short % of Float	24.93%
Short Ratio (days to cover)	5.59

Income Statement

In the last 12 months, Novavax had revenue of $987.67 million and -$294.33 million in losses. Loss per share was -$2.28.

Revenue	987.67M
Gross Profit	159.76M
Operating Income	-286.23M
Pretax Income	-288.88M
Net Income	-294.33M
EBITDA	-240.84M
EBIT	-286.23M
Loss Per Share	-$2.28

Balance Sheet

The company has $1.05 billion in cash and $263.54 million in debt, giving a net cash position of $786.06 million or $4.91 per share.

Cash & Cash Equivalents	1.05B
Total Debt	263.54M
Net Cash	786.06M
Net Cash Per Share	$4.91
Equity (Book Value)	-431.71M
Book Value Per Share	-2.70
Working Capital	45.56M

Cash Flow

In the last 12 months, operating cash flow was $14.28 million and capital expenditures -$36.75 million, giving a free cash flow of -$22.47 million.

Operating Cash Flow	14.28M
Capital Expenditures	-36.75M
Free Cash Flow	-22.47M
FCF Per Share	-$0.14

Margins

Gross margin is 16.18%, with operating and profit margins of -28.98% and -29.80%.

Gross Margin	16.18%
Operating Margin	-28.98%
Pretax Margin	-29.25%
Profit Margin	-29.80%
EBITDA Margin	-24.38%
EBIT Margin	-28.98%
FCF Margin	-2.39%

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-54.60%
Shareholder Yield	-54.60%
Earnings Yield	-20.16%
FCF Yield	-1.54%

Analyst Forecast

The average price target for Novavax is $17.83, which is 95.50% higher than the current price. The consensus rating is "Buy".

Price Target	$17.83
Price Target Difference	95.50%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	-2.34%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05:1

Scores

Novavax has an Altman Z-Score of -3.42 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.42
Piotroski F-Score	4